Compare
Anavex Life Sciences Corp. vs Surrozen, Inc. vs Lineage Cell Therapeutics, Inc. vs Zura Bio Ltd
| Latest fiscal year | Anavex Life Sciences Corp. AVXL | Surrozen, Inc. SRZN | Lineage Cell Therapeutics, Inc. LCTX | Zura Bio Ltd ZURA |
|---|---|---|---|---|
| Year ended | 2025-09-30 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $3.48M | $14.56M | n/a |
| Revenue growth (YoY) | n/a | -67.4% | +53.2% | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/m | -251.6% | n/a |
| Net margin | n/a | n/m | -436.5% | n/a |
| Net income | -$46.38M | -$242.03M | -$63.53M | -$68.65M |
| EPS (Diluted) | -$0.54 | -$32.37 | -$0.28 | -$1.06 |
| Operating cash flow | -$39.04M | -$30.24M | -$18.92M | -$64.81M |
| Free cash flow | n/a | -$30.37M | -$19.44M | -$64.93M |
| Cash & equivalents | $102.58M | $89.25M | $40.79M | $109.41M |
| Total assets | $103.81M | $98.73M | $112.58M | $113.95M |
| Total liabilities | $8.95M | $286.49M | $69.24M | $12.41M |
| Shareholders' equity | $94.87M | -$187.76M | $43.35M | $101.54M |
| Return on year-end equity | -48.9% | n/a | -146.6% | -67.6% |
| Shares outstanding | 86.67M | 9.78M | 243.12M | 73.68M |
Revenue, most recent five fiscal years
| Fiscal year | Anavex Life Sciences Corp. | Surrozen, Inc. | Lineage Cell Therapeutics, Inc. | Zura Bio Ltd |
|---|---|---|---|---|
| Latest | n/a | $3.48M Ended 2025-12-31 | $14.56M Ended 2025-12-31 | n/a |
| 1 year earlier | n/a | $10.65M Ended 2024-12-31 | $9.50M Ended 2024-12-31 | n/a |
| 2 years earlier | n/a | $0 Ended 2023-12-31 | $8.95M Ended 2023-12-31 | n/a |
| 3 years earlier | n/a | $12.50M Ended 2022-12-31 | $14.70M Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | $0 Ended 2021-12-31 | $4.34M Ended 2021-12-31 | n/a |